Sign in
CLYYF Stock Price, Chart, Stats & News
Celyad Oncology S.A.
Save
Celyad Oncology S.A. (CLYYF) does not currently pay a dividend.
12.53M
Market cap
1647.06x
Current P/E
–
Forward P/E
CLYYF chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Celyad Oncology SA is a clinical-stage biopharmaceutical entity dedicated to the discovery and advancement of chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment. Its prominent clinical programs include CYAD-101, an allogeneic CAR-T candidate in a Phase 1b trial for metastatic colorectal cancer. Another significant asset is CYAD-211, an allogeneic CAR-T therapy based on short hairpin RNA (shRNA), currently undergoing Phase 1 evaluation for relapsed/refractory multiple myeloma.
Similar securities
Based on sector and market capitalization
Report issue